Compare Amphastar Pharmaceuticals Inc (AMPH) vs Apollo Global Management Ord Shs (APO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Apollo Global Management Ord Shs — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Apollo Global Management Ord Shs trades at $140.17 (market cap $76.04B). The key difference: Apollo Global Management Ord Shs is far larger — about 88× Amphastar Pharmaceuticals Inc's market cap, and Apollo Global Management Ord Shs pays a 1.7% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | APO | |
|---|---|---|
Market Cap | $863.95M | $76.04B |
Sector | Health | Financials |
52-Week High | $30.81 | $152.70 |
52-Week Low | $16.87 | $100.30 |
Enterprise Value | $1.26B | -$175.45B |
Dividend Yield | — | 1.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Apollo Global Management (APO) trades at $127.44, down 0.43% today but maintains a bullish technical outlook with strong analyst support. The company reported mixed Q2 2026 results with an EPS miss but record $60 billion quarterly inflows, driving AUM to $1.05 trillion. Valuation metrics show a P/E of 45.35 and P/S of 2.11, with solid profitability margins and consistent dividend payments.
APO presents a compelling investment case with strong institutional backing and growth in fee-related earnings, though elevated P/E and recent earnings miss warrant caution. The consensus price target of $151.50 suggests 19% upside potential, supported by the company's leadership in private credit and AI infrastructure expansion initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Apollo Global Management Ord Shs
Apollo Global Management Inc is an alternative investment manager. It serves various sectors such as chemicals, manufacturing and industrial, natural resources, consumer and retail, consumer services, business services, financial services, leisure, and media and telecom and technology. The company operates in three business segments that are Private Equity, Credit, and Real Assets. It generates maximum revenue from the Credit segment in the form of fees. The credit segment primarily invests in non-control corporate and structured debt instruments including performing, stressed and distressed instruments across the capital structure. It also includes Corporate Credit
Read more on APO →
